Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression

Pathology International

Volumn 60, Issue 11, 2010, Pages 735-743

  Hagikura, Minako ^a   Murakumo, Yoshiki ^a   Hasegawa, Masaki ^b   Jijiwa, Mayumi ^a   Hagiwara, Sumitaka ^a   Mii, Shinji ^a   Hagikura, Shoichi ^a   Matsukawa, Yoshihisa ^a   Yoshino, Yasushi ^a   Hattori, Ryohei ^a   Wakai, Kenji ^a   Nakamura, Shigeo ^c   Gotoh, Momokazu ^a   Takahashi, Masahide ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

CD109; CD44; Immunohistochemistry; Phospho Smad2; Urothelial carcinoma

Indexed keywords

GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HERMES ANTIGEN; PROTEIN CD109; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER EPITHELIUM; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; UROGENITAL TRACT TUMOR; UROTHELIAL CARCINOMA;

ANTIGENS, CD; CARCINOMA; FEMALE; GPI-LINKED PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM PROTEINS; NEOPLASM STAGING; PHOSPHORYLATION; SMAD2 PROTEIN; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 77958484263     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2010.02592.x     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009; 374: 239-49.
3. Wallerand H, Bernhard JC, Culine S et al. Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways. Urol Oncol 2009; in press.
4. Van Rhijn BWG, Burger M, Lotan Y et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: From epidemiology to treatment strategy. Eur Urol 2009; 56: 430-42.
5. Sylvester RJ, Van Der Meijden APM, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466-77.
6. Wu XR. Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer 2005; 5: 713-25.
7. Knowles MA. Molecular pathogenesis of bladder cancer. Int J Clin Oncol 2008; 13: 287-97.
8. Neal DE, Marsh C, Bennett MK et al. Epidermal-growth-factor receptors in human bladder cancer: Comparison of invasive and superficial tumours. Lancet 1985; 1: 366-8.
9. Cappellen D, De Oliveira C, Ricol D et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999; 23: 18-20.
10. Zhang ZT, Pak J, Huang HY et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 2001; 20: 1973-80.
11. Abdel-Fattah R, Challen C, Griffiths TR, Robinson MC, Neal DE, Lunec J. Alteration of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: High frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer 1998; 77: 2230-38.
12. Cairns P, Proctor AJ, Knowles MA. Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene 1991; 6: 2305-9.
13. Spruck CH 3rd, Ohneseit PF, Gonzalez-Zulueta M et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994; 54: 784-8.
14. Sutherland DR, Yeo E, Ryan A, Mills GB, Bailey D, Baker MA. Identification of a cell-surface antigen associated with activated T lymphoblasts and activated platelets. Blood 1991; 77: 84-93.
15. Lin M, Sutherland DR, Horsfall W et al. Cell surface antigen CD109 is a novel member of the c2 macroglobulin/C3, C4, C5 family of thioester-containing proteins. Blood 2002; 99: 1683-91.
16. Hashimoto M, Ichihara M, Watanabe T et al. Expression of CD109 in human cancer. Oncogene 2004; 23: 3716-20.
17. Zhang JM, Hashimoto M, Kawai K et al. CD109 expression in squamous cell carcinoma of the uterine cervix. Pathol Int 2005; 55: 165-9.
18. Hasegawa M, Hagiwara S, Sato T et al. CD109, a new marker for myoepithelial cells of mammary, salivary, and lacrimal glands and prostate basal cells. Pathol Int 2007; 57: 245-50.
19. Sato T, Murakumo Y, Hagiwara S et al. High-level expression of CD109 is frequently detected in lung squamous cell carcinomas. Pathol Int 2007; 57: 719-24.
20. Hasegawa M, Moritani S, Murakumo Y et al. CD109 expression in basal-like breast carcinoma. Pathol Int 2008; 58: 288-94.
21. Hagiwara S, Murakumo Y, Sato T et al. Up-regulation of CD109 expression is associated with carcinogenesis of the squamous epithelium of the oral cavity. Cancer Sci 2008; 99: 1916-23.
22. Finnson KW, Tam BY, Liu K et al. Identification of CD109 as part of the TGF-β receptor system in human keratinocytes. FASEB J 2006; 20: 1525-7.
23. Hagiwara S, Murakumo Y, Mii S et al. Processing of CD109 by furin and its role in the regulation of TGF-beta signaling. Oncogene 2010; 29: 2181-91.
24. Chan KS, Espinosa I, Chao M et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 2009; 106: 14016-21.
25. Yang YM, Chang JW. Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: Novel methods for isolating undetermined cancer stem (initiating) cells. Cancer Invest 2008; 26: 725-33.
26. Murray LJ, Bruno E, Uchida N et al. CD109 is expressed on a subpopulation of CD34+ cells enriched in hematopoietic stem and progenitor cells. Exp Hematol 1999; 27: 1282-94.
27. Polyak K, Hahn WC. Roots and stems: Stem cells in cancer. Nat Med 2005; 7: 296-300.
28. Haregewoin A, Solomon K, Hom RC et al. Cellular expression of a GPI-linked T cell activation protein. Cell Immunol 1994; 156: 357-70.
29. Caballero OL, Chen YT. Cancer/testis (CT) antigens: Potential targets for immunotherapy. Cancer Sci 2009; 100: 2014-21.
30. Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM, Schalken JA. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 1993; 53: 3241-5.
31. Garcia del Muro X, Torregrosa A, Muñoz J et al. Prognostic value of the expression of E-cadherin and b-catenin in bladder cancer. Eur J Cancer 2000; 36: 357-62.
32. Bierie B, Moses HL. Tumour microenvironment: Tgfβ: The molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 6: 506-20.
33. Massague J. TGFβ in Cancer. Cell 2008; 134: 215-30.
34. Tokunaga H, Lee DH, Kim IY, Wheeler TM, Lerner SP. Decreased expression of transforming growth factor β receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients. Clin Cancer Res 1999; 5: 2520-25.
35. Kim JH, Shariat SF, Kim IY et al. Predictive value of expression of transforming growth factor-β1 and its receptors in transitional cell carcinoma of the urinary bladder. Cancer 2001; 92: 1475-83.
36. Izadifar V, De Boer WI, Muscatelli-Groux B, Maille P, Van Der Kwast TH, Chopin DK. Expression of transforming growth factor βl and its receptors in normal human urothelium and human transitional cell carcinomas. Hum Pathol 1999; 30: 372-7.